NCT03617484撤回2 期
Phase II Study Evaluating the Effect of Adding Bortezomib to Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The proportion of participants that respond to treatment at 6 months
研究概览
简要总结
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 18 years of age
- •Diagnosis of mantle cell lymphoma established by histologic assessment by a hemato-pathologist with additional assessment of the histologic diagnosis by immunohistochemistry or flow cytometry.
- •Patients with history of MCL that has relapsed (documented disease progression after previously responding) to therapy (CR/PR) on single agent ibrutinib (treated for at least 6 months) as the last treatment prior to enrollment.
- •Adequate liver, renal and bone marrow function
- •Adequate coagulation (unless abnormalities are unrelated to coagulopathy or bleeding disorder)
- •Female subjects of childbearing potential must have a negative urine/serum pregnancy test upon study entry. Women as well are not advised to breastfeed during treatment with bortezomib and for 2 months after treatment.
- •Male and female subjects of reproductive potential must agree to use both a highly effective method of birth control and barrier method during the period of therapy and for 30 days after the last dose of study drug for females and 90 days for males.
- •Eastern Cooperative Oncology Group (ECOG) performance status of <2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.)
排除标准
- •Concurrent diagnosis of another malignancy unless treated with curative intent more than 2 years from study start (basal/squamous cell carcinoma of the skin is not an exclusion).
- •Previous treatment with bortezomib.
- •Patients who are eligible for autologous stem cell transplant are excluded unless they refuse this procedure.
- •History of allogeneic stem cell transplant.
- •Other exclusions (certain concurrent conditions) per protocol
研究组 & 干预措施
Bortezomib + Ibrutinib
Experimental
Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
干预措施: Bortezomib (Drug)
Bortezomib + Ibrutinib
Experimental
Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
干预措施: Ibrutinib (Drug)
结局指标
主要结局
The proportion of participants that respond to treatment at 6 months
时间窗: 6 Months
The primary endpoint is overall response rate (ORR). Participants will be evaluated for response based on the Lugano criteria.
次要结局
- Rate of complete response(Up to 10 Years)
- Time to progression(Up to 10 Years)
- Overall survival time(Up to 10 Years)
- Progression free survival time(Up to 10 Years)
- Best overall response(Up to 10 Years)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisImmunoglobulin Light Chain DepositionAmyloidosisNCT03130348Mayo Clinic
Unknown
2 期
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsOvarian Neoplasm EpithelialHigh Grade Serous CarcinomaNCT03509246Seoul National University Hospital44
进行中（未招募）
1 期
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT02537613Dana-Farber Cancer Institute54
已完成
1 期
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Acute Myeloid LeukemiaAdult Pure Erythroid Leukemia (M6b)Untreated Adult Acute Myeloid LeukemiaNCT00742625National Cancer Institute (NCI)95
已完成
1 期
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT00972712Emory University12